Form 4: IRADIMED CEO Sells Shares Under 10b5-1 Plan

IRADIMED Corporation's CEO, Roger E. Susi, reported multiple sales of common stock totaling 7,500 shares in late March 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, CEO, President, Chairman, and 10% Owner of IRADIMED Corporation, reported the sale of 7,500 shares of common stock.
• The sales occurred over two days: March 23, 2026, and March 24, 2026.
• Transactions on March 23, 2026, included sales of 2,950 shares at a weighted average price of $99.58, 750 shares at $100.70, and 1,300 shares at $102.02.
• Transactions on March 24, 2026, included sales of 1,585 shares at a weighted average price of $100.03 and 915 shares at $100.71.
• All reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Roger E. Susi on November 5, 2025.
• Following these transactions, Roger E. Susi's beneficial ownership includes 2,232,500 shares indirectly held by the Phillip Susi 2008 Dynasty Trust, 162,950 shares indirectly held by the Roger E. Susi Revocable Trust, and 2,062,500 shares indirectly held by the Matthew Susi 2008 Dynasty Trust (with a disclaimer of beneficial ownership except for pecuniary interest).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling reduces direct equity exposure, the pre-arranged nature under a 10b5-1 plan mitigates concerns about reactive selling based on new negative information.

Positives

• The sales were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured approach to liquidity or diversification rather than a reactive decision based on immediate company news.

Negatives

• Insider selling, even if pre-planned, reduces the direct equity stake of a key executive and can be perceived as a slight negative by some investors, potentially signaling a lack of conviction or a need for personal liquidity.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025."
• "The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose." (Regarding shares held by Matthew Susi 2008 Dynasty Trust)

Industry Context

StockSavvy.ai notes that insider sales, even when executed under a Rule 10b5-1 plan, are routinely monitored by investors for potential signals regarding management's confidence in the company's future prospects or their personal liquidity needs. Such pre-planned sales are generally viewed with less concern than unexpected, open-market sales.

Related Party Transactions

• Roger E. Susi's beneficial ownership includes shares held indirectly through various family trusts: Phillip Susi 2008 Dynasty Trust, Roger E. Susi Revocable Trust, and Matthew Susi 2008 Dynasty Trust. These represent related party interests.

Stakeholder Impact

• Shareholders might perceive a slight negative signal from the reduction in direct insider holdings, although the pre-planned nature of the sales under a 10b5-1 plan typically lessens the impact compared to unplanned sales.

Key Dates

Recommendation

The sales by CEO Roger E. Susi were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reactive decision based on new information. While insider selling can sometimes be a negative signal, the pre-planned nature and the amounts involved do not suggest a fundamental shift in the company's outlook that would warrant a change from a 'hold' position based solely on this filing.

Keywords

IRADIMED, IRMD, insider trading, Form 4, stock sale, CEO, Roger Susi, 10b5-1 plan, beneficial ownership